Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the standard first line treatment for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, the optimal treatment after progression on osimertinib is unknown. We examined real-world practice patterns of second line systemic therapy after osimertinib to better understand variability in managing this scenario in the U.S. and associated outcomes.